Angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy;ANGIOTENSINKONVERTERENDE ENZYM-HAEMMERBEHANDLING AF EPIRUBICININDUCERET DILATERET KARDIOMYOPATI

Ugeskrift for Laeger

Volumn 159, Issue 13, 1997, Pages 1945-1949

  Jensen, Benny Vittrup ^a   Nielsen, Steen Levin ^a   Jensen, Torben Skovsgaard ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE; EPIRUBICIN; FUROSEMIDE; RAMIPRIL;

ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DILATATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOMYOPATHY, DILATED; ENALAPRIL; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED;

EID: 0030895602     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Mortensen SA, Aabo K, Jonsson T, Baandrup U. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection. Int J Clin Pharmacol Res 1986; 6: 137-50.
2. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 827-34.
3. Von Hoff DD, Layard MW, Basa P, Davis HL, Jr., Von Hoff AL, Rozencweig et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.
4. Nielsen D, Jensen JB, Dombernowsky P, Munck O, Fogh J, Brynjolf I et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990; 8: 1806-10.
5. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.
6. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. QRS voltage change with adriamycin administration. Cancer Treat Rep 1978; 62: 931-4.
7. Haq MM, Legha SS, Choksi J, Hortobagyi GNN, Benjamin RS, Ewer M et al. Doxorubicin-induced congestive heart failure in adults. Cancer 1985; 56: 1361-65.
8. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of pa-tients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 1: 255-9.
9. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429-35.
10. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol 1993; 14: 9-12.
11. Nielsen D, Dombernowsky P, Skovsgaard T, Jensen J, Andersen E, Engelholm SA et al. Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study. Ann Oncol 1990; 1: 275-80.
12. Brynjolf I, Kelbaek H, Munck O, Godtfredsen J, Larsen S, Eriksen J. Right and left ventricular ejection fraction and left ventricular volume changes at rest and during exercise in normal subjects. Eur Heart J 1984; 5: 756-61.
13. Lee DC, Johnson RA, Bingham JB, Leahy M, Dinsmore RE, Goroll AH et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med 1982; 306: 699-705.
14. Lenaz L, Page JA Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 1976; 3: 111-20.
15. Dardir MD, Ferrans VJ, Mikhael YS, el-Grindy MS, el-Aasar AB, el-Zawahry et al. Cardiac morphologic and functional changes induced by epirubicin chemotherapy. J Clin Oncol 1989; 7: 947-58.
16. Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986; 46: 3722-7.
17. Caulfield JB, Bittner V. Cardiac matrix alterations induced by adriamycin. Am J Pathol 1988; 133: 298-305.
18. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65.
19. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12-6A